Indinavir

• CAT Number: I001862
• CAS Number: 150378-17-9
• Molecular Formula: C36H47N5O4
• Molecular Weight: 613.79
• Purity: ≥95%
• Target: HIV Protease
• Solubility: water：0.02 mg/mL
• Storage: Desiccate at RT
• InChI: InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
• InChIKey: CBVCZFGXHXORBI-PXQQMZJSSA-N
• SMILES: O=C([C@H]1N(C[C@@H](O)C[C@@H](CC2=CC=CC=C2)C(N[C@@H]3[C@H](O)CC4=C3C=CC=C4)=O)CCN(CC5=CC=CN=C5)C1)NC(C)(C)C

Indinavir (CAT: I001862), also known as MK-639 or L735524, is a potent and specific inhibitor of HIV protease. It belongs to the class of antiretroviral drugs known as protease inhibitors and is used in the treatment of HIV/AIDS. Indinavir works by inhibiting the activity of the HIV protease enzyme, which is essential for the replication of the virus. By blocking this enzyme, indinavir helps to prevent the cleavage of viral polyproteins, ultimately reducing the production of mature infectious viral particles. Indinavir is often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) to effectively suppress HIV replication and improve the immune function of individuals living with HIV/AIDS.

Reference

1: Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique
Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.
[Evidence-based therapeutic drug monitoring for indinavir]. Therapie. 2011
May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Review.
French. PubMed PMID: 21819808.

2: Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient
with renal insufficiency and pyuria. Clin Nephrol. 1998 Sep;50(3):194-6. Review.
PubMed PMID: 9776425.

3: Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH.
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir,
and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75. Review. PubMed PMID:
9297727.

4: Chefchaouni MC, Thiounn N, Flam T, Zerbib M, Debré B. [Urinary calculi and
indinavir sulfate in patients with HIV infection. Apropos of 4 cases]. J Urol
(Paris). 1997;103(1-2):35-6. Review. French. PubMed PMID: 9765778.

5: Lacy MK, Abriola KP. Indinavir: a pharmacologic and clinical review of a new
HIV protease inhibitor. Conn Med. 1996 Dec;60(12):723-7. Review. PubMed PMID:
9018893.